1 / 14

Use of RIB facilities for producing isotopes for cancer treatment by DART

Use of RIB facilities for producing isotopes for cancer treatment by DART. Itzhak Kelson Tel Aviv University & Althera Medical Ltd. DART in a nutshell.

nelle-rocha
Télécharger la présentation

Use of RIB facilities for producing isotopes for cancer treatment by DART

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Use of RIB facilities for producing isotopes for cancer treatment by DART Itzhak Kelson Tel Aviv University & Althera Medical Ltd

  2. DART in a nutshell • DART (Diffusing Alpha-emitters Radiation Therapy): a new concept in radiation therapy which may enable therapeutic tumor doses with negligible damage to nearby healthy tissue • Comprises three elements: • The use of alpha particles rather than photons or electrons • Enhancement of the therapeutic range of alpha particles from microns to millimeters • Utilization of the different properties of malignant and healthy tissues to ensure minimal collateral damage

  3. Alpha particle essentials • Emitted by readily available isotopes • Densely ionizing (LET ≈ 100 keV/ µm) • Range in tissue: 40 – 90 µm • Possess all benefits of high-LET radiation: • Direct ionization of the DNA  complex DNA lesions • Biological effect insensitive to hypoxia, dose rate, cell cycle • Single hit to the nucleus may induce cell death • Short range may guarantee sparing adjacent tissue … but also limits the use against solid tumors

  4. The idea • Rather than a source that emits alpha particles - a source that emits alpha-emitting atoms • The source is impregnated with small activities of 224Ra • When 224Ra decays its daughter atoms recoil out of the source (Emax~100 keV) • The atoms disperse near the source, forming a cluster of alpha emissions extending over several millimeters

  5. Generator α Implanted Source 212Bi 224Ra decay chain 228Th α 1.91 y α α 220Rn 224Ra 216Po 212Pb 0.15 s 55.6 s 3.66 d β 10.64 h Diffusing Atoms α 208Tl 60.6 m β β 60.6 m 3.05 m α 212Po 208Pb 0.3 µs stable

  6. - V 228Th panel + V Source preparationelectrostatic collection of 224Ra Needle (source) Field lines

  7. A B C D E F All: 212Pb autoradiography of murine squamous cell carcinoma (SQ2)

  8. Mouse treated with a placebo source Mouse treated with a 800 nCi source

  9. Source preparation (future plant) 228Th +V -V Typical dimensions: L=100 cm, R=3 cm Typical 228Th activity: 10 μCi/cm2 Each unit produces ~2000 treatments/year

  10. Design criteria for 228Th generators • 228Th activity ~10 μCi/cm2 • 224Ra desorption probability ~40% • No knock-out of 228Th atoms • Safe, low-cost production • Long operational lifetime

  11. α 228Ra 228Th 227Ac 228Fr 228Ac 226Ra 228Ac 228Th 227Ra 228Th 232U 1.9 y 42 m 1.9 y 1600 y 38 s 6.2 h 6.2 h 5.8 y 22 y 1.9 y 69 y β β β β β 228Th Production Schemes (n,γ) σ=13b (n,γ) σ=902b

  12. 228Fr scheme - quantitative aspects • Typical DART treatment ~100 μCi 224Ra (1.7×1012 atoms) • 228Th atoms per treatment ~1013 • Assuming 228Fr production rate of 1012 atoms/s: ~10 seconds per treatment ~200 seconds per cm2 of generator

  13. Design criteria for 228Th generators - RIB • 228Th activity ~10 μCi/cm2 • 224Ra desorption probability ~40% • No knock-out of 228Th atoms • Safe, low-cost production • Long operational lifetime

More Related